Introduction
The interactions between proteins and drugs have attracted considerable attention in the research community in recent years. 1 Serum albumins are the major soluble protein constituents in the circulatory system, and helpful in maintaining colloidal osmotic blood pressure and pH of blood and also aid in the transportation and deposition of many endogenous and exogenous compounds, such as fatty acids, amino acids and drugs. 1, 2 Therefore, investigation of the binding mechanism between drug and protein (including binding affinity, binding site and binding forces) would provide much information for profoundly understanding the pharmacological actions of the drug and the relationships of their structures and functions, 3 which are very important for evaluation of drug efficacy. Furthermore, the drug-protein interaction can provide scientific evidence for development of novel drugs. 3 Human serum albumin (HSA), produced in the liver, is the extreme abundant serum protein present in blood plasma, and it is also found in tissues and secretions throughout the body. HSA is a single-chain 66 kDa globular protein containing 585 amino acid residues with only 1 tryptophan and 17 tyrosines. It accounts for approximately 60% of the total protein in blood serum. 4 A total of 17 disulfide bridges maintain the stability of the protein. HSA is usually selected as the model protein to probe the interaction of drugs with protein because of its structural characteristics. The structure of HSA has been characterized and comprise three homologous domains (I, II, III), which are further divided into two sub-domains (IA, IB, IIA, IIB, IIIA and IIIB), consisting individually of six and four α-helices. 2 It is known that two major structurally selective and high affinity drug binding sites are located in subdomains IIA and IIIA, named Sudlow's site I and site II, respectively. HSA can undergo several different pH dependent conformational transitions, the N-F transition between pH 7.0 and 3.5. 5 Although conformation of HSA is complex, there is only a sole tryptophan in the protein in domain II, which makes it very convenient to study HSA via intrinsic fluorescence.
Chalcones, a sub-class of flavonoids that widely exist in fruits and vegetable, are the proverbial precursors of natural plants and intermediates of synthetic bioactive compounds. 6, 7 Chalcones are an open-chained compound composed of two aromatic rings connected by a three-carbon enone fragment (Fig. S1 , Supporting Information). 8 Due to greater flexibility in the molecular structure of chalcone and capable of binding to different receptors, chalcones possess a broad spectrum of † To whom correspondence should be addressed. Chalcones are the proverbial precursors of many naturally occurring compounds and possess a variety of biological activities and a broad spectrum of pharmacological properties. The interaction mechanism between three chalcones, 2′,4′,4-trihydroxyflavone (also called isoliquiritigenin, 2′,4′,4-triHC), 2′,4′-dihydroxyflavone (2′,4′-diHC), and 4-hydroxyflavone (4-HC) and human serum albumin (HSA) was investigated using fluorescence quenching, fluorescence enhancement and UV absorption spectra. The binding parameters of chalcone-HSA complexes were evaluated by fluorescence quenching measurements, and the results were consistent with those obtained from fluorescence enhancement methods. The binding affinities of three chalcones with HSA at pH 7.4 were ranked in the order (the binding constants in the range 0.28 -2.39 × 10 5 L mol biological activity, such as antibacterial, antifungal, anticancer and anti-inflammatory properties. [8] [9] [10] [11] The anticancer activity of chalcones is primarily ascribed to its phenolic hydroxyl groups that exhibit high affinity to proteins and thus could inhibit the growth of cancer cells. Chalcones that exist in licorice root can restrain the proliferation of established and primary ovarian cancer cells. 12 Chalcone derivatives replaced via carboxyl demonstrated comparatively strong CysLT1 antagonistic activity. 13 In addition, chalcone derivatives showed potent inhibition of acetylcholinesterase (AChE) and the inhibition of AChE activity has been approved for the present treatment of Alzheimer's disease (AD).
14 Moreover, chalcones can inhibit the activity of the Mycobacterium tuberculosis protein tyrosine phosphatase A (PtpA), an enzyme combined with M. tuberculosis infectivity. 15 Hesperidin methyl chalcones have vasoprotective activity and may cure acute hemorrhoid and chronic venous insufficiency. 16 Bombardelli et al. 17 found that the chalcones derivatives, such as 2′,4′,4-triHC and 2′,4′-diHC, exhibited a significant affinity to estrogen receptors of type II, and a conspicuous anti-proliferative activity on ovary, uterus and breast tumor cell lines. Moreover, 2′,4′,4-triHC displayed significant chemopreventive activities against lung, breast, prostate, and colorectal cancers. 18 In addition, 4-HC and chalcone analogues have been shown to possess an outstanding inhibitory effect on phosphorylation and the partial uncoupling. 19 In the present study, the interaction of three chalcones (2′,4′,4-trihydroxyflavone (2′,4′,4-triHC), 2′,4′-dihydroxyflavone (2′,4′-diHC), and 4-hydroxyflavone (4-HC)) with HSA was explored using fluorescence quenching, fluorescence enhancement and UV absorption spectrometric techniques, and the binding parameters of chalcone-protein complexes were estimated. The binding site of 2′,4′,4-triHC to protein was probed through observing their spectroscopic properties in the buffer solution at pH 7.4 and 3.5, and then the binding mode of the drug to the protein was discussed. The obtained results provided a variety of scientific data to understand the interaction mechanism of chalcones and protein, which they would be beneficial for the development of novel drugs with a similar structural skeleton.
Experimental

Reagents and chemicals
HSA (essentially fatty acid free, ≥99%) and three kinds of chalcones (≥97%) were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and were used with no further purification. NaOH, H3PO4 and NaH2PO4 were obtained from Beijing Red Star Chemical Plant (Beijing, China). All the aqueous solutions were prepared using ultrapure water made from Barnstead EASYpure LF ultrapure water purification (Boston, America). All other chemicals were analytical reagent grade.
Preparation of stock solutions: HSA was dissolved in aqueous solution with the concentration of 10 mmol L -1 phosphate buffer solution. The concentrated stock solutions of chalcones were prepared in methanol and small aliquots were received from this stock solution. The final methanol concentration in the solutions was less than 5% (v/v). The pH of the phosphate buffer solution was changed to 2.0, 3.5, 4.5, 6.4, 7.4 and 8.4 by adding NaOH or H3PO4 solution to NaH2PO4 solution. NaCl solution was used to adjust the ion strength of solutions to 0.1 mmol L -1 . All measurements were conducted at 25 C.
Apparatus and methods UV absorbance spectroscopy. The UV absorbance spectra For the fluorescence enhancement experiment, the concentration of chalcone was 10 μM in pH 7.4 and 3.5 buffer solutions. The protein to drug molar ratios were 0.1, 0.3, 0.5, 0.7, 1.0, 1.5, 2.0, 2.5 and 3.0, respectively. The excitation wavelengths of 2′,4′,4-triHC were set at 440 nm (pH 7.4) and 350 nm (pH 3.5), and the excitation wavelengths of 2′,4′-diHC and 4-HC in pH 7.4 buffer solution were 380 and 350 nm, respectively. The excitation and emission band widths were both 5 nm.
Results and Discussion
Fluorescence quenching mechanism of HSA by chalcones
The fluorescence quenching method can provide a wealth of information for the interaction of drugs with protein, including the binding affinity, number of binding sites, and binding site. 20 The fluorescence of protein is mainly derived from the amino acid residues of tryptophan or tryosin. For HSA, the single tryptophan (Trp-214) is located in hydrophobic subdomain IIA. The fluorescence of protein only originates from Trp-214 after excitation at 295 nm and both tryptophan and tyrosine at 280 nm.
2 Figure 1 shows the fluorescence quenching spectra of HSA induced by different concentrations of 2′,4′,4-triHC (A), 2′,4′-diHC (C) and 4-HC (D) in phosphate buffer solution with pH 7.4, and 2′,4′,4-triHC with pH 3.5 (B) at the excitation wavelength of 280 nm. As shown in Fig. 1 , the fluorescence intensities of the protein are significantly quenched by increasing the Cdrug/CHSA ratio from 0.1 to 10. Furthermore, the fluorescence quenching degree of the protein induced by these chalcones in pH 7.4 buffer solution is larger than those in pH 3.5, and it may be that the conformation of human serum albumin and drugs under acid conditions is changed.
From the profiles of the fluorescence quenching spectra for the protein, it can be seen that the maximum fluorescence emission bands of HSA after interaction with 2′,4′,4-triHC, 2′,4′-diHC and 4-HC presented blue shifts of 2, 18 and 13 nm (at pH 7.4), respectively. The results illustrated that the interactions between chalcones and the proteins have changed the conformation of the protein and the tryptophan residues of the protein have been exposed to a more hydrophobic environment. 21 The Stern-Volmer quenching constant KD and the bimolecular quenching rate constant kQ were obtained by using the SternVolmer equation (Eq. (1)). 22
Where F0 and F are the fluorescence intensities of a protein in the absence and presence of the drug, [Q] is the drug concentration, and τ0 represents the average lifetime of the fluorophore in the absence of the drug. From Fig. S2 , it can be found that the curve was nonlinear and showed an upward curvature at higher drug concentrations. This indicated that the quenching mechanism was probably a mixture of static and dynamic quenching processes.
The Stern-Volmer plots were linear in the molar ratio of 2′,4′,4-triHC to protein ranging from 0.1 to 4.0 at pH 7.4 and 3.5, respectively, and when the 2′,4′-diHC and 4-HC to protein molar ratio ranged from 0.1 to 1.0 and 0.1 to 1.5, at pH 7.4, respectively, the Stern-Volmer plot presented as a linear curve. The average fluorescence lifetime of HSA was 5 ns, 24 and so the bimolecular quenching rate constants (kQ) acquired according to Eq. (1) are listed in These results indicated that the fluorescence quenching process of HSA by three chalcones was mainly a static quenching. 25 Furthermore, these drugs and HSA formed complexes.
If the fluorescence quenching was a static process, the number of the binding site (n) and the binding constants (KA) can be calculated through Eq. (2) deduced in our previous report.
From Table 1 , the n values from the slopes of the Eq. (2) were about 1 when the molar ratio 2′,4′,4-triHC to protein ranged from 0.1 to 6.0 and 0.1 to 5.0 at pH 7.4 and 3.5, respectively, and when the 2′,4′-diHC and 4-HC to protein molar ratio at pH 7.4 ranged from 0.1 to 2.0. This indicated that three kinds of chalcones combined with HSA were 1:1. The average of experiments (n = 5), and their relative standard deviation was less than 3%.
If the number of binding sites was one (n ≈ 1), Eq. (2) can be changed to Eq. (3), and the binding affinities of the drug and protein can be calculated from the slopes of the double reciprocal
The plot of F0/(F0 -F) versus [Q]
-1 for the chalcone-protein complexes was examined (Fig. 2) . The double reciprocal curves were linear in the range from 0.1 to 10.0 of three chalcones to HSA molar ratio at pH 7.4 and 3.5, respectively. The calculation results obtained according to Eq. (3) are listed in Table 1 Table S1 , Supporting Information), which confirmed that the binding affinities were credible and reliable.
In addition, the reduction of the solution acidity from pH 7.4 to 3.5 can lead to the structure change of HSA from N to F state. In the F state, the domain III, namely site II of the protein, would be exposed, which can cause a loss of interaction between domains II and III. However, the binding constant value of 2′,4′,4-triHC and HSA in pH 7.4 solution was little different from that at pH 3.5. Besides, the similar spectroscopic properties of 2′,4′,4-triHC-protein complexes at pH 7.4 and 3.5 solutions indicated that 2′,4′,4-triHC bound in domain II (site I) of HSA. 5 
UV absorption spectra of HSA by three chalcones
The three chalcones have a similar structural skeleton, and the only difference was the numbers or position for the substituents of their hydroxyl group (see Fig. S1 ). The UV absorption spectra of chalcone usually have two main bands, Band I (340 -390 nm) and Band II (220 -270 nm). The Band I is possible from the conjugated system of B-ring and the carbonyl group in the molecule and Band II is attributed to the absorption for the conjugated system of A-ring and the carbonyl group. Figure S3 shows the UV absorption spectra of three chalcones in the phosphate buffer solutions with various pH values. Figure 3A shows the UV absorption spectra for different concentrations of 2′,4′,4-triHC in the absence and presence of HSA at pH 7.4. It can be seen from Fig. 3A that there is a main absorption band at 385 nm for the Band I of the free 2′,4′,4-triHC in phosphate buffer solution at pH 7.4 (Fig. 3A, line a) . After adding the drug in low concentration to the protein, the maximum UV absorption peak of 2′,4′,4-triHC shifted from 385 to 400 nm (Fig. 3A, line b) . This suggested that the phenol hydroxyl group at four positions of 2′,4′,4-triHC have been dissociated, and the drug combined with the protein in anion. With the increase of the drug concentration, the absorption peak from 400 nm shifted to 395 nm, which could be because of the overlap on the UV absorption spectra between drug-protein complex and the free drug. 27 There is a maximum peak at 373 nm and a shoulder peak at 320 nm for the Band I of the free 2′,4′-diHC in phosphate buffer solution at pH 7.4 (Fig. 3B, line a) . A red shift 25 nm was observed from the maximum absorption peak of 2′,4′-diHC with 50 μmol L -1 concentration (Fig. 3B, line b) , and the absorption intensity increased markedly when 50 μmol L -1 HSA was added, which indicated that the phenol hydroxyl group of 2′,4′-diHC was disassociated, and the drug bound with the protein in an anionic form. With the addition of the drug concentration, the absorption peak shifted from 398 to 393 nm, which could be due to the overlap on the UV absorption spectra between drug-protein complex and the free drug. In addition, the shoulder peak at 320 nm changed to a subsidiary peak with the addition of 2′,4′-diHC concentration, whereas no changes in the peak position were observed (Fig. 3B, lines c -f ) .
Meanwhile, 4-HC exhibited a maximum absorption peak in 349 nm for the Band I in phosphate buffer solution at pH 7.4 (Fig. 3C, line a) . After interacting with the protein, the maximum absorption peak of 4-HC shifted from 349 to 356 nm (Fig. 3C, lines c -f ) , and the absorption intensity increased markedly. These results demonstrated that the phenol hydroxyl group of the drug was disassociated, and the drug bound to the protein in an anionic form. It was interesting to know that a new shoulder peak of 4-HC at about 422 nm appeared after interacting with HSA and the intensity of absorption spectra increased along with increasing concentration of 4-HC. The results are evidence of the 4-HC-HSA complex formation in the interaction study.
A significant red shift in the absorption of B-ring of chalcones after interacting with protein revealed that three kinds of chalcones and HSA formed complexes, respectively, and chalcone bound to protein in anionic forms and the ionic interaction was the main interaction force for the chalconeprotein complexes. Furthermore, the UV absorption studies signified that the conjugated system formed by B-ring and the molecular carbonyl was supposed to have taken part in the interaction with HSA.
Fluorescence enhancement of three chalcones in the presence of HSA
Figures S4A and S4B (Supporting Information) exhibit the fluorescence enhancement spectra of 2′,4′,4-triHC in the absence and presence of diverse concentrations of HSA in pH 7.4 ( Fig. S4A ) and pH 3.5 ( Fig. S4B) buffer solution, individually. As shown in Figs. S4A and S4B, the fluorescence emission spectra of the free 2′,4′,4-triHC showed extremely weakly fluorescent emission bands at the excitation wavelength of 440 nm (pH 7.4, Fig. S4A ) and 350 nm (pH 3.5, Fig. S4B ), respectively. Similar to 2′,4′,4-triHC, 2′,4′-diHC and 4-HC also have very weakly fluorescent emission bands, when the excitation wavelength was at 380 nm ( Fig. S4C ) and 350 nm (Fig. S4D) at pH 7.4, respectively. With the addition of the protein, the fluorescence emission bands of the three chalcones enhanced significantly, which verified that three kinds of chalcones formed complexes with the protein. The emission bands of 2′,4′,4-triHC have red shifts from 561 to 566 nm at pH 7.4 (Fig. S4A) , and from 457 to 440 nm at pH 3.5 (Fig. S4B) , respectively, when HSA concentration increased continuously. From Figs. S4C and S4D, it can be seen that there was not a distinct shift in the emission bands of 2′,4′-diHC with the enhancement of HSA concentration at the excitation wavelength of 380 nm (pH 7.4, Fig. S4C ), and the emission bands of 4-HC shifted from 492 to 502 nm at the excitation wavelength of 350 nm (pH 7.4, Fig. S4D ). The red shifts of the emission bands for the chalcones suggested that the combinations of drug and protein resulted in the structural changes of the chalcones. 25 These were consistent with the above conclusions that drug-HSA complexes have formed. In addition, 2′,4′,4-triHC, 2′,4′-diHC and 4-HC all showed single fluorescence emission bands along with the fluorescence intensity increasing obviously after interacting with HSA, which may be due to the excited state intramolecular proton transfer (ESPT). 5, 24 The binding constants between drug and protein can be determined from the fluorescence enhancement data according to the Benesi-Hildebrand equation. 27 
Here, ΔF = Fx -F0 and ΔFmax = F∞ -F0, where F0, Fx and F∞ are the fluorescence intensities of the drug in the absence of HSA, at protein concentration and at a concentration for complete interaction, individually. K is the binding constant and [L] is the protein concentration. The above equation can be modified as: Figure 4 showed the plots of
of 2′,4′,4-triHC and HSA system at pH 7.4 and 3.5. From the figure, it can be seen that the graphs were two straight lines, which suggested that the combination between drug and protein was a one-to-one relationship. 
Summary and Conclusions
The binding modes of three different structural chalcones (2′,4′,4-triHC, 2′,4′-diHC and 4-HC) with human serum albumin (HSA) have been investigated by fluorescence quenching, fluorescence enhancement and UV absorption spectrometric methods. The fluorescence intensities of the protein were significantly quenched with increasing concentrations of the chalcones in pH 7.4 and 3.5 buffer solutions with the blue shift of the maximum fluorescence emission bands. This illustrated that the complexes between chalcones and the proteins were formed and the interactions changed the conformation of the protein, which led to the tryptophan residues of the protein exposed to a more hydrophobic environment. Chalcones can obviously quench the intrinsic fluorescence of the amino acid residues in protein and the fluorescence quenching mechanism was mainly a static quenching process. The binding affinities of the three chalcones and HSA were obtained by fluorescence quenching and fluorescence enhancement method (0.28 -2.39 × 10 5 L mol -1 ), and the results revealed that three kinds of chalcones can intensively bind with HSA. The binding constants of three kinds of chalcones bound with HSA in pH 7.4 were in the order 2′,4′,4-triHC > 2′,4′-diHC > 4-HC, which demonstrated that the binding affinities of chalcone and the protein in pH 7.4 were positive correlated to the number of phenolic hydroxyl groups in the chalcone molecules, and it is deduced that the hydroxyl groups played an important role in the combination processes. The molecular ratios of three chalcones bound to HSA were 1:1 obtained by the fluorescence quenching measurement, which was consistent with the fluorescence enhancement measurement. The intrinsic fluorescence of chalcone significantly enhanced after interacting with protein due to the excited-state proton transfer (ESPT), which further verified that the chalcone-protein complexes were formed.
A clear red shift of the UV absorption band of three chalcones after interacting with protein revealed that the hydroxyl groups on the chalcone molecules were disassociated in the chalconeprotein complexes and chalcone bound to the protein in anionic form. The similar spectroscopic properties of 2′,4′,4-triHCprotein complexes at pH 7.4 and 3.5 solutions demonstrated that 2′,4′,4-triHC, in anionic form, bound within the hydrophobic pockets of subdomain IIA of HSA (site I). The electrostatic force and ionic interactions played a crucial role in the binding interaction between chalcones and protein. The obtained results provided scientific evidence for the binding mechanism of the chalcones and protein, which would be helpful to comprehensively understand the pharmacological properties of the chalcones and also beneficial for developing novel drugs based on the structural skeleton of the chalcones.
